ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

QDEL vs NTLA // EV/EBITDA & P/E VALUATION

QuidelOrtho Corporation (NASDAQ) VS. Intellia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: QDEL 3 — NTLA 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QDEL VS. NTLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC QDEL NTLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -8.80% -21.35% +12.55 QDEL /fcf-yield <GO>
Operating Margin -33.70% -60.00% +26.30 QDEL /operating-margins <GO>
Net Profit Margin -41.50% -60.00% +18.50 QDEL /net-margins <GO>
Revenue Growth (YoY) -1.90% 16.90% -18.80 NTLA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 1.17 -0.97 NTLA /balance-sheet <GO>
Piotroski F-Score Quality 4/9 4/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.1 53.4 -2.37 NTLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $943.6M $1.85B -$910.3M NTLA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR QDEL REV NTLA REV QDEL GROSS % NTLA GROSS % QDEL FCF NTLA FCF
FY 2025 $2.73B $67.7M — — -$83.0M -$395.9M
FY 2024 $2.78B $57.9M — — -$112.1M -$354.7M
FY 2023 $3.00B $36.3M — — $280.2M -$394.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QDEL // BETA —
NTLA // BETA —